AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Lilly’s Zepbound Cut Risk of Diabetes by 94% in Obese People
Bloomberg Businessweek
Intro
3min Snip
00:00
Summary
Transcript
Episode notes
This chapter examines a three-year study revealing Eli Lilly's ZEP Bound significantly reduces diabetes risk by 94% in patients. It underscores the importance of long-term data on GLP-1 drugs, showcasing their enduring benefits in weight management and chronic disease prevention.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode